Apollo Medical Holdings In Investor Presentation Reiterates 2023 Guidance
$AMEH
Professional Services
Consumer Discretionary
Apollo Medical Holdings In Investor Presentation Reiterates 2023 Guidance
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/22/2024 | $44.00 → $55.00 | Neutral → Buy | BofA Securities |
| 1/24/2024 | $45.00 | Buy | Stifel |
| 12/22/2023 | $41.00 | Hold | Truist |
| 10/17/2023 | $45.00 | Buy | BTIG Research |
| 4/12/2023 | $44.00 | Neutral | BofA Securities |
| 12/19/2022 | $40.00 | Buy | Lake Street |
| 9/21/2022 | Outperform | William Blair | |
| 1/11/2022 | $93.00 | Buy | Colliers Securities |
SC 13G/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)
SC 13D/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)
SC 13G/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)
ALHAMBRA, Calif., Jan. 29, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced a strategic long-term partnership with BASS Medical Group, one of the largest multi-specialty medical groups in the Greater San Francisco Bay Area. The partnership will bolster BASS Medical Group's value-based care and operational infra
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Akido, a tech-integrated medical network reimagining healthcare from the ground up, announced that Eric Chin has been appointed Chief Financial Officer, effective immediately. Chin will work closely with Akido's co-founders as the company continues to bring its unique blend of AI-powered technology, best-in-class medical services and scalable preventive care programs to new markets across the U.S. Previously, Chin served as Chief Financial Officer at Apollo Medical Holdings (ApolloMed), a publicly traded physician-centric technology-powered healthcare company (NASDAQ:AMEH) that increased reported total revenue from approximately $520 million i
CERRITOS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ:TOI) today announced the appointment of Mihir Shah as chief financial officer, effective immediately. In this role, Mr. Shah will lead the Accounting, Finance, Revenue Cycle Management, and Investor Relations functions, playing a key role in driving TOI's public company success and executing the strategic growth plan. Mr. Shah succeeds Scott Dalgleish, who will serve as a senior advisor through a transition period. Mr. Shah joins TOI with fifteen years of industry leadership experience across public, private, and not-for-profit organizations. Most recently Mr. Shah served as chief fi
ALHAMBRA, Calif., Jan. 31, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2023, after the close of the stock market on Tuesday, February 27, 2024. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.
Company to Host Conference Call on Monday, August 7, 2023, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., Aug. 7, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the second quarter ended June 30, 2023. Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, "Our strong
ALHAMBRA, Calif., July 28, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it will release financial results for the second quarter ended June 30, 2023, after the close of the stock market on Monday, August 7, 2023. The Company will discuss those results in a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.
4 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)
3 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)
4 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)
8-K - Astrana Health, Inc. (0001083446) (Filer)
8-K - Astrana Health, Inc. (0001083446) (Filer)
8-K - Astrana Health, Inc. (0001083446) (Filer)
BofA Securities upgraded Apollo Medical from Neutral to Buy and set a new price target of $55.00 from $44.00 previously
Stifel initiated coverage of Apollo Medical with a rating of Buy and set a new price target of $45.00
Truist initiated coverage of Apollo Medical with a rating of Hold and set a new price target of $41.00
Apollo Medical Hlgs (NASDAQ:AMEH) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.15 by 73.33 percent. The company reported quarterly sales of $353.04 million which beat the analyst consensus estimate of $340.61 million by 3.65 percent. This is a 20.00 percent increase over sales of $294.21 million the same period last year.
Apollo Medical Hlgs (NASDAQ:AMEH) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement. Analysts estimate that Apollo Medical Hlgs will report an earnings per share (EPS) of $0.15. Apollo Medical Hlgs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.14, which was followed by a 9.08% i
Jefferies analyst Jack Slevin initiates coverage on Apollo Medical Hlgs (NASDAQ:AMEH) with a Buy rating and announces Price Target of $50.
ALHAMBRA, Calif., Feb. 22, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, announced today it will formally change its name from Apollo Medical Holdings, Inc. ("ApolloMed") to Astrana Health, Inc. ("Astrana Health"). As previously announced, the Company will begin trading under the ticker symbol "ASTH." Both changes will take effect February 26, 2024.
ALHAMBRA, Calif., Jan. 31, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2023, after the close of the stock market on Tuesday, February 27, 2024. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.
ALHAMBRA, Calif., Jan. 29, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced a strategic long-term partnership with BASS Medical Group, one of the largest multi-specialty medical groups in the Greater San Francisco Bay Area. The partnership will bolster BASS Medical Group's value-based care and operational infra